{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T00:25:59Z","timestamp":1783124759006,"version":"3.54.6"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2020,7,27]],"date-time":"2020-07-27T00:00:00Z","timestamp":1595808000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,7,27]],"date-time":"2020-07-27T00:00:00Z","timestamp":1595808000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arch Gynecol Obstet"],"published-print":{"date-parts":[[2020,9]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n<jats:title>Purpose<\/jats:title>\n<jats:p>Mutations in the genes <jats:italic>BRCA1<\/jats:italic> and <jats:italic>BRCA2<\/jats:italic> represent a significant risk factor for ovarian and breast cancer. With increasing number and success rates, fertility protection and treatment are gaining importance also for <jats:italic>BRCA1\/2<\/jats:italic> mutation carriers. However, the effect on primary cancer risk and risk for recurrence remains unclear. This review analyses the published data on fertility treatment and risk of ovarian and breast cancer in <jats:italic>BRCA1\/2<\/jats:italic> mutation carriers.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Methods<\/jats:title>\n<jats:p>In this review, we included all relevant articles published in English from 1995 to 2018. Literature was identified through a search on PubMed and Cochrane Library.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Results<\/jats:title>\n<jats:p>We identified one retrospective cohort and one case\u2013control study regarding the association of fertility treatments and ovarian cancer risk in <jats:italic>BRCA<\/jats:italic> mutation carriers. The studies show no increase in ovarian cancer risk. Furthermore, one case\u2013control study on the association between fertility treatment and breast cancer risk in <jats:italic>BRCA<\/jats:italic> mutation carriers and one prospective cohort study on the long-term safety of medication used for fertility preservation in women with a history of breast cancer were identified. One of the studies shows a possible adverse effect for gonadotropin-containing medication.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Conclusion<\/jats:title>\n<jats:p>Possible increases in cancer risk associated with fertility treatments in <jats:italic>BRCA1\/2<\/jats:italic> mutation carriers cannot be excluded at this time. Based on the existing studies, <jats:italic>BRCA1\/2<\/jats:italic> mutation carriers should not be generally excluded from fertility treatments. However, they have to be informed about limited data and possible increases in cancer risk.<\/jats:p>\n<\/jats:sec>","DOI":"10.1007\/s00404-020-05690-4","type":"journal-article","created":{"date-parts":[[2020,7,27]],"date-time":"2020-07-27T10:02:48Z","timestamp":1595844168000},"page":"715-720","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Use of fertility treatments in BRCA1\/2 mutation carriers and risk for ovarian and breast cancer: a systematic review"],"prefix":"10.1007","volume":"302","author":[{"given":"D.","family":"Huber","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Seitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Kast","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Emons","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6238-3949","authenticated-orcid":false,"given":"O.","family":"Ortmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,7,27]]},"reference":[{"issue":"4","key":"5690_CR1","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1097\/GCO.0000000000000370","volume":"29","author":"L Kroener","year":"2017","unstructured":"Kroener L, Dumesic D, Al-Safi Z (2017) Use of fertility medications and cancer risk: a review and update. Curr Opin Obstet Gynecol 29(4):195\u2013201","journal-title":"Curr Opin Obstet Gynecol"},{"key":"5690_CR2","first-page":"CD008215","volume":"6","author":"I Rizzuto","year":"2019","unstructured":"Rizzuto I, Behrens RF, Smith LA (2019) Risk of ovarian cancer in women treated with ovarian stimulating drugs for infertility. Cochrane Database Syst Rev 6:CD008215","journal-title":"Cochrane Database Syst Rev"},{"issue":"1","key":"5690_CR3","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1056\/NEJM199407073310102","volume":"331","author":"M Lambe","year":"1994","unstructured":"Lambe M, Hsieh C, Trichopoulos D, Ekbom A, Pavia M, Adami HO (1994) Transient increase in the risk of breast cancer after giving birth. N Engl J Med 331(1):5\u20139","journal-title":"N Engl J Med"},{"issue":"1","key":"5690_CR4","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1038\/sj.bjc.6602302","volume":"92","author":"G Albrektsen","year":"2005","unstructured":"Albrektsen G, Heuch I, Hansen S, Kv\u00e5le G (2005) Breast cancer risk by age at birth, time since birth and time intervals between births: exploring interaction effects. Br J Cancer 92(1):167\u2013175","journal-title":"Br J Cancer"},{"issue":"9609","key":"5690_CR5","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1016\/S0140-6736(08)60167-1","volume":"371","author":"V Beral","year":"2008","unstructured":"Beral V, Doll R, Hermon C, Peto R, Reeves G (2008) Ovarian cancer and oral contraceptives: collaborative reanalysis of data from 45 epidemiological studies including 23,257 women with ovarian cancer and 87,303 controls. Lancet 371(9609):303\u2013314","journal-title":"Lancet"},{"issue":"23","key":"5690_CR6","doi-asserted-by":"publisher","first-page":"2402","DOI":"10.1001\/jama.2017.7112","volume":"317","author":"KB Kuchenbaecker","year":"2017","unstructured":"Kuchenbaecker KB, Hopper JL, Barnes DR, Phillips K-A, Mooij TM, Roos-Blom M-J et al (2017) Risks of breast, ovarian, and contralateral breast cancer for BRCA1 and BRCA2 mutation carriers. JAMA 317(23):2402\u20132416","journal-title":"JAMA"},{"issue":"2","key":"5690_CR7","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1200\/JCO.2009.24.2057","volume":"28","author":"K Oktay","year":"2010","unstructured":"Oktay K, Kim JY, Barad D, Babayev SN (2010) Association of BRCA1 mutations with occult primary ovarian insufficiency: a possible explanation for the link between infertility and breast\/ovarian cancer risks. J Clin Oncol 28(2):240\u2013244","journal-title":"J Clin Oncol"},{"issue":"1","key":"5690_CR8","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1093\/annonc\/mdx639","volume":"29","author":"M Lambertini","year":"2018","unstructured":"Lambertini M, Goldrat O, Ferreira AR, Dechene J, Azim HA, Desir J et al (2018) Reproductive potential and performance of fertility preservation strategies in BRCA-mutated breast cancer patients. Ann Oncol 29(1):237\u2013243","journal-title":"Ann Oncol"},{"issue":"4","key":"5690_CR9","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1093\/jnci\/djx206","volume":"110","author":"M Lambertini","year":"2018","unstructured":"Lambertini M, Kroman N, Ameye L, Cordoba O, Pinto A, Benedetti G et al (2018) Long-term safety of pregnancy following breast cancer according to estrogen receptor status. J Natl Cancer Inst 110(4):426\u2013429","journal-title":"J Natl Cancer Inst"},{"issue":"suppl 15","key":"5690_CR10","doi-asserted-by":"publisher","first-page":"11506","DOI":"10.1200\/JCO.2019.37.15_suppl.11506","volume":"37","author":"M Lambertini","year":"2019","unstructured":"Lambertini M, Ameye L, Hamy A-S, Zingarello A, Poorvu PD, Carrasco E, Grinshpun A, Han S, Rousset-Jablonski C, Ferrari A, Paluch-Shimon S, Cortesi L, Senechal C, Miolo G, Pogoda K, Perez-Fidalgo JA, De Marchis L, Del Mastro L, Peccatori F, Azim HA (2019) Safety of pregnancy following breast cancer (BC) in patients (pts) carrying a BRCA mutation (mBRCA): results of an international cohort study. J Clin Oncol 37(suppl 15):11506","journal-title":"J Clin Oncol"},{"issue":"5","key":"5690_CR11","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1016\/j.fertnstert.2015.02.011","volume":"103","author":"T Perri","year":"2015","unstructured":"Perri T, Lifshitz D, Sadetzki S, Oberman B, Meirow D, Ben-Baruch G et al (2015) Fertility treatments and invasive epithelial ovarian cancer risk in Jewish Israeli BRCA1 or BRCA2 mutation carriers. Fertil Steril 103(5):1305\u20131312","journal-title":"Fertil Steril"},{"issue":"3","key":"5690_CR12","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1016\/j.fertnstert.2015.11.034","volume":"105","author":"J Gronwald","year":"2016","unstructured":"Gronwald J, Glass K, Rosen B, Karlan B, Tung N, Neuhausen SL et al (2016) Treatment of infertility does not increase the risk of ovarian cancer among women with a BRCA1 or BRCA2 mutation. Fertil Steril 105(3):781\u2013785","journal-title":"Fertil Steril"},{"issue":"10","key":"5690_CR13","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1007\/s10552-008-9175-0","volume":"19","author":"J Kotsopoulos","year":"2008","unstructured":"Kotsopoulos J, Librach CL, Lubinski J, Gronwald J, Kim-Sing C, Ghadirian P et al (2008) Infertility, treatment of infertility, and the risk of breast cancer among women with BRCA1 and BRCA2 mutations: a case\u2013control study. Cancer Causes Control 19(10):1111\u20131119","journal-title":"Cancer Causes Control"},{"issue":"4","key":"5690_CR14","doi-asserted-by":"publisher","first-page":"1364","DOI":"10.1210\/jc.2015-3878","volume":"101","author":"J Kim","year":"2016","unstructured":"Kim J, Turan V, Oktay K (2016) Long-term safety of letrozole and gonadotropin stimulation for fertility preservation in women with breast cancer. J Clin Endocrinol Metab 101(4):1364\u20131371","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"5690_CR15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/gepi.20074","volume":"29","author":"AC Antoniou","year":"2005","unstructured":"Antoniou AC, Goldgar DE, Andrieu N, Chang-Claude J, Brohet R, Rookus MA et al (2005) A weighted cohort approach for analysing factors modifying disease risks in carriers of high-risk susceptibility genes. Genet Epidemiol 29(1):1\u201311","journal-title":"Genet Epidemiol"},{"issue":"7","key":"5690_CR16","doi-asserted-by":"publisher","first-page":"djw302","DOI":"10.1093\/jnci\/djw302","volume":"109","author":"KB Kuchenbaecker","year":"2017","unstructured":"Kuchenbaecker KB, McGuffog L, Barrowdale D, Lee A, Soucy P, Dennis J et al (2017) Evaluation of polygenic risk scores for breast and ovarian cancer risk prediction in BRCA1 and BRCA2 mutation carriers. J Natl Cancer Inst 109(7):djw302","journal-title":"J Natl Cancer Inst"},{"issue":"1","key":"5690_CR17","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1158\/1055-9965.EPI-11-0775","volume":"21","author":"N Mavaddat","year":"2012","unstructured":"Mavaddat N, Barrowdale D, Andrulis IL, Domchek SM, Eccles D, Nevanlinna H et al (2012) Pathology of breast and ovarian cancers among BRCA1 and BRCA2 mutation carriers: results from the consortium of investigators of modifiers of BRCA1\/2 (CIMBA). Cancer Epidemiol Biomarkers Prev 21(1):134\u2013147","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"5690_CR18","unstructured":"Krebs in Deutschland 2011\/2012: Eine gemeinsame Ver\u00f6ffentlichung des Robert Koch-Instituts und derGesellschaft der epidemiologischen Krebsregister in Deutschland e. V. [10. Ausgabe]. Berlin; 2015"},{"issue":"22","key":"5690_CR19","doi-asserted-by":"publisher","first-page":"2154","DOI":"10.1056\/NEJMoa1611310","volume":"375","author":"MR Mirza","year":"2016","unstructured":"Mirza MR, Monk BJ, Herrstedt J, Oza AM, Mahner S, Redondo A et al (2016) Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer. N Engl J Med 375(22):2154\u20132164","journal-title":"N Engl J Med"},{"issue":"3","key":"5690_CR20","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1007\/s10549-013-2823-4","volume":"143","author":"J Kotsopoulos","year":"2014","unstructured":"Kotsopoulos J, Lubinski J, Moller P, Lynch HT, Singer CF, Eng C et al (2014) Timing of oral contraceptive use and the risk of breast cancer in BRCA1 mutation carriers. Breast Cancer Res Treat 143(3):579\u2013586","journal-title":"Breast Cancer Res Treat"}],"container-title":["Archives of Gynecology and Obstetrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00404-020-05690-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00404-020-05690-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00404-020-05690-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,26]],"date-time":"2021-07-26T23:26:23Z","timestamp":1627341983000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00404-020-05690-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,27]]},"references-count":20,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020,9]]}},"alternative-id":["5690"],"URL":"https:\/\/doi.org\/10.1007\/s00404-020-05690-4","relation":{},"ISSN":["0932-0067","1432-0711"],"issn-type":[{"value":"0932-0067","type":"print"},{"value":"1432-0711","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7,27]]},"assertion":[{"value":"30 March 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 July 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 July 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}